Skip to main content

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Active, not recruiting · Not applicable · NCT05409989

Conditions: Intracranial Aneurysm

At a glance

Research payments reported, 2025
$644,547
U.S. investigators named
25
Sites paid
23
Planned or actual enrollment
154

About the trial

Sponsor
Microvention-Terumo, Inc.
Tested
FRED™ X™ (device)
Dates
Started 2022-09-20; completion 2030-05
Results posted
Not yet

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

From ClinicalTrials.gov, last updated 2026-03-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Microvention, Inc. reported $644,547 in research payments for this study in 2025 (170 payments).

Products named: Stent, Web Aneurysm Embolization System, Sofia 6f-131cm Str, Hydrosoft Advanced, Hypersoft Advanced

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.